$599

Structure Tx Oral GLP-1RA Ph2a Results; Akero Doses First Patients in EFX Ph3 Program

Two cardiometabolic-related news items have been observed: Structure Therapeutics announced Ph2a study results and program updates for its oral GLP-1RA (GSBR-1290) and hosted an associated webcast (view webcast; slides); and Akero Therapeutics announced the first patients have been dosed in the SYNCHRONY Ph3 program evaluating efruxifermin (EFX) in MASH (view press release). Below, FENIX provides highlights and insights for the respective news items.

About The Author

Matthew Maryniak

|
President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.